|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||25.0200 - 25.6000|
|52 Week Range||24.2300 - 29.5000|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.00%|
Silver Spring biotech United Therapeutics Corp.'s share price was largely unchanged Friday after announcing it settled litigation with Actavis Laboratories FL Inc. in a deal that will allow that company to market a generic version of one of United Therapeutics' hypertension drugs. Under the settlement, United Therapeutics (UTHR) grants the Teva Pharmaceutical Industries Ltd. (TEVA) subsidiary a license to manufacture and commercialize a generic version of Orenitram — an extended-release, oral tablet form of treprostinil —beginning June 15, 2027. Actavis had filed a challenge seeking to market the generic Orenitram before United Therapeutics' patents expire between 2024 and 2031.
United Therapeutics has settled patent litigation over a $157 million drug. The company (UTHR) reached an agreement with Actavis Laboratories FL, which is a subsidiary of generic giant Teva Pharmaceuticals, that resolves litigation over certain patents related to one of United Therapeutics' pulmonary arterial hypertension drugs: Orenitram. The settlement agreement allows Actavis to begin manufacturing and commercializing a generic version of the drug in June 2027 or potentially earlier under some circumstances. However, United Therapeutics noted that the agreement doesn't allow Actavis to manufacture generic versions of other products like Tyvaso or Remodulin.
Allergan (AGN.N) will make a one-time payment of $700 million to Teva Pharmaceutical Industries (TEVA.TA) to settle a dispute over working capital, Israel-based Teva said on Thursday. Teva will use the payment, which is expected during the first quarter of 2018, to repay part of its debt. Teva (TEVA.N) and Allergan agreed to jointly dismiss the working capital dispute arbitration.
Exchange traded funds tied to marijuana skidded on Thursday on a report that Attorney General Jeff Sessions planned to roll back the measure that encouraged more states in recent years to legalize usage of the plant.
Hedge funder Bill Ackman and Valeant Pharmaceuticals will pay $290 million to settle claims from shareholders in Allergan they engaged in insider trading when pressing a takeover of the botox-maker in 2014. The settlement means Valeant likely cost Pershing $4 billion.
Pershing Square said it decided to raise its share of the settlement to 66.8 percent, or $193.75 million, in a bid to quickly wind up the litigation, which it claimed had "no merit". "We decided, however, that it was in the best interest of our investors to settle the case now instead of continuing to spend substantial time and resources pursuing the litigation," said Pershing Square CEO Bill Ackman. The hedge fund said Valeant will now pay around 33 percent, or $96.25 million, of the settlement costs.
Triple-leveraged ETFs – funds that mainly use futures to ratchet up the exposure to a specific asset – have long been considered one of Wall Street’s riskiest products. This week, those funds take a back seat to the newly launched quadruple-leveraged exchange-traded notes brought to the market by Citigroup.
AdvisorShares, an exchange traded fund provider known for its actively managed investment options, has launched a new ETF that capitalizes on vice and also one among the first to include targeted exposure ...
BETHESDA, Md., Dec. 11, 2017 /PRNewswire/ -- AdvisorShares, a leading sponsor of actively managed exchange-traded funds (ETFs), announced today that the AdvisorShares Vice ETF (Ticker: ACT) will begin trading on Tuesday, December 12, 2017. ACT becomes the first ETF – among both passively managed and actively managed strategies – that provides concentrated exposure to select companies associated with alcohol, cannabis and tobacco. ACT's portfolio management team carries extensive experience in the capital markets and a well-established expertise of investing in this area of the equity markets, which includes the founder and original portfolio manager of the Vice Fund mutual fund (VICEX).
Teva Pharmaceutical Industries , the world's largest generic drugmaker, said on Wednesday it was looking for a buyer for its Medis business as it sells assets to pare down its debt burden. Teva, which last week reported a drop in second-quarter results and cut its outlook and dividend, acquired Iceland-based Medis as part of its acquisition of Actavis last year. "Teva is looking at every opportunity to focus our business and streamline operations, processes and structure," Teva said in an emailed statement to Reuters.
Eli Lilly and Co won a years-long patent dispute with Actavis on Friday after the UK Supreme Court ruled that the generic drugmaker's versions of Lilly's top-selling cancer drug Alimta directly infringe on certain Lilly patents in Britain, France, Italy and Spain. Teva Pharmaceutical Industries Ltd owns the generic versions of Alimta in question after buying Allergan Plc's generic business Actavis last August.
LONDON (AP) — Britain's Supreme Court has ruled in favor of Eli Lilly and Co. in a patent dispute with generic drug-maker Actavis over Lilly's Alimta cancer treatment.
Lilly sued Actavis, saying its generic product would still infringe on Lilly's vitamin regimens regardless of any dilution.
Eli Lilly & Co. won a patent dispute with Actavis at the U.K.’s top court, marking a victory in a long-running legal campaign to defend its third best-selling drug, Alimta, from rival products.